secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000899923-23-000075
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics appoints Sam Raha as COO effective Dec 11, 2023
---------------------------------------------------------------

- Base salary $750k; annual target cash bonus 75% of base; sign-on bonus $500k with clawback provisions.
- Initial RSU grant of $4M (two tranches of $2M each based on stock price at hiring announcement and start date).
- Eligible for additional RSU grant of $2-3M in 2024, 50% time-vesting and 50% performance-vesting.
- Raha previously President of Agilent Diagnostics & Genomics Group and VP Global Marketing at Illumina.
- Raha will oversee lab operations, customer service, and product development innovations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000075/0000899923-23-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000075/mygn-20231101.htm
  HTML page:      https://secwatch.observer/filing/0000899923-23-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer